The present disclosure relates in general to patient monitoring systems including a patient monitor, one or more optical sensors, and a communication cable or device transferring signals between the monitor and the sensor(s).
Standard of care in caregiver environments includes patient monitoring through spectroscopic analysis using, for example, oximeter technologies commercially available from Masimo Corporation of Irvine. Devices capable of spectroscopic analysis generally include light sources transmitting optical radiation into a measurement site, such as, body tissue carrying pulsing blood. After attenuation (e.g. via transmission through tissue, reflectance, etc.) by tissue and fluids of the measurement site, one or more photodetection devices detects the attenuated light and outputs one or more detector signals responsive to the detected attenuated light. One or more signal processing devices process the detector(s) signal(s) and output a measurement indicative of a blood constituent of interest, such as, glucose, oxygen, methemoglobin, total hemoglobin, other physiological parameters, or other data or combinations of data useful in determining a state or trend of wellness of a patient. Such combinations often include statistical analysis of one or more measurements or combinations of different parameter measurements into useful information.
In addition to the foregoing, considerable efforts have been made to develop noninvasive oximeter techniques for measuring other blood analytes or patient parameters, including for example, glucose, total hemoglobin, or the like. Unfortunately, some of these parameters have proven to be difficult to measure using noninvasive spectroscopy. For example, the biologic tissue and water of a measurement site have a high intrinsic absorption at many of the wavelengths of light that are useful in measuring blood glucose. Moreover, blood glucose exists in relatively low concentrations comparatively with other blood analytes. Furthermore, different patients will have large variations in the optical properties of their skin and blood composition.
Moreover, ambient and/or environment interference (i.e., noise) can adversely affect the measurement accuracy. Interference is generated by many commonly-used electrical devices. In a typical household for example, electric power lines and outlets, ambient lights, light dimmers, television or computer displays, and power supplies or transformers generate electromagnetic interference. For example, noise caused by ambient light will generally vary with a periodicity corresponding to a 50 Hz or 60 Hz fundamental frequency and its harmonics. As will be understood by those of skill in the art, the ambient light frequency is a function of the frequency of electricity powering the ambient lights and other interfering devices and/or the frequency of naturally occurring light. The ambient light frequency will, accordingly, change depending on the power system used to operate the devices creating the ambient light. Harmonics of the fundamental ambient light frequency are important because the ambient light can still cause significant interference at the harmonic frequencies. This is particularly true when the ambient light is provided by fluorescent lights which generate significant noise at the second harmonic (i.e., 100 Hz or 120 Hz) and the fourth harmonic (i.e., 200 Hz or 240 Hz). In addition in typical care environments medical equipment (e.g., electrocauterization devices) also generates significant electromagnetic interference. These and other challenges make signal information indicative of physiological parameters (e.g., glucose) difficult to differentiate from the interference signal. Moreover, patients and other users often desire glucose and other physiological parameter data in at least spot check measurements in a wide variety of care and non-care environments where interference levels are unknown.
In some embodiments of the present disclosure, an interference detector configured to reliably measure the levels of ambient and/or environment interference is described. The detector utilizes frequency analysis to determine and calculate interference levels in the frequency bands of interest. Such bands of interest can be configured to be those frequencies used for analysis during measuring the various physiological parameters. For example, a modulated light signal attenuated by body tissue or fluids can comprise physiological information at the fundamental frequency and harmonic frequencies of the carrier signal (e.g., a periodic pulse train). Interference levels can be measured at the fundamental frequency and harmonic frequencies to determine the likelihood of obtaining reliable measurements of physiological parameters in the presence of ambient and/or environment noise.
In some embodiments of the present disclosure, the interference levels can be computed as energy or power of interference signals concentrated at the frequencies of interest. The maximum measured power can be used to determine the worst-case effect of ambient and/or environmental interference on the accuracy of measurements of physiological parameters. This maximum measured power can be compared with a threshold to obtain an objective determination of the significance of the interference and its expected degradation of the accuracy of the measurements. The threshold can be selected as a multiple of the noise floor of the interference detector or, in other words, the measured noise signal that is inherently present in the system because of thermal noise, shot noise, and the like. The noise floor further establishes a limit on the smallest measurement that can be reliably preformed by the system. The multiple of the noise floor and the threshold can be varied depending on the type of physiological parameter being measured by the device.
In some embodiments of the present disclosure, the interference detector can be configured to provide audio-visual indication of the measured interference levels, relative to the threshold, to the user. Visual indication can comprise displaying bar graphs, charts, graphs, and the like of the measured, relative interference levels. Audio indication can comprise speaking the severity of the measured, relative interference levels. Audio-visual indication can be helpful in spot check measurement situations because the user can be quickly informed as to the expected accuracy of the measurement of physiological parameters. In addition, the user can be quickly alerted in situations where ambient and/or environmental interference can significantly degrade the measurement accuracy or cause the measurements be unreliable.
For purposes of summarizing the invention, certain aspects, advantages and novel features of the invention have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the invention.
The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.
Ambient and/or environment interference (i.e., noise) can adversely affect the measurement accuracy of non-invasive patient monitoring systems, such as systems capable of measuring glucose, oxygen, methemoglobin, total hemoglobin, and other physiological parameters. To perform the measurements, these systems typically utilize signal processing analysis of optical radiation (e.g., light) signal detected by photodetectors after it has been attenuated by body tissue and fluids. However, significant interference is generated by many commonly-used electrical devices, such as electric power lines and outlets, ambient lights, light dimmers, television or computer displays, power supplies or transformers, and medical equipment (e.g., electrocauterization devices). It can be difficult to differentiate signal information indicative of physiological parameters from the interference. Moreover, patients and other users often desire glucose and other physiological parameter data in at least spot check measurements in a wide variety of care and non-care environments where the interference levels are unknown.
Existing solutions for measuring the interference levels can be inadequate, especially in spot check situations. For example, one approach is to measure the interference at the same time as performing measurements of physiological parameters. However, this can be unreliable because interference may be highly non-stationary and non-periodic, may have short-duration components with significant energy levels, and so on. Accordingly, such measurements of interference levels can be inaccurate and unreliable.
In some embodiments of the present disclosure, an interference detector configured to reliably measure the interference levels is described. The detector utilizes frequency analysis to determine and calculate interference levels in the frequency bands of interest. Such bands of interest can be configured to be those frequencies used for analysis during measuring the various physiological parameters. For example, a modulated light signal attenuated by body tissue or fluids can comprise physiological information at the fundamental frequency and harmonic frequencies of the carrier signal (e.g., a periodic pulse train). Interference levels can be measured at the fundamental frequency and harmonic frequencies to determine the likelihood of obtaining reliable measurements of physiological parameters in the presence of ambient and/or environment noise. In some embodiments, the interference levels can be used to determine a best modulation rate that will result in the least interference to the desired signal.
In some embodiments of the present disclosure, the interference levels can be computed as energy or power of interference signals concentrated at the frequencies of interest. The maximum measured power can be used to determine the worst-case effect of ambient and/or environmental interference on the accuracy of measurements of physiological parameters. This maximum measured power can be compared with a threshold to obtain an objective determination of the significance of the interference and its expected degradation of the accuracy of the measurements. The threshold can be selected as a multiple of the noise floor of the interference detector or, in other words, the measured noise signal that is inherently present in the system because of thermal noise, shot noise, and the like. The noise floor further establishes a limit on the smallest measurement that can be reliably performed by the system. The multiple of the noise floor and the threshold can be varied depending on the type of physiological parameter being measured by the device.
In some embodiments of the present disclosure, the interference detector can be configured to provide audio-visual indication of the measured interference levels, relative to the threshold, to the user. Visual indication can comprise displaying bar graphs, charts, graphs, and the like of the measured, relative interference levels. Audio indication can comprise speaking the severity of the measured, relative interference levels. Audio-visual indication can be helpful in spot check measurement situations because the user can be quickly informed as to the expected accuracy of the measurement of physiological parameters. In addition, the user can be quickly alerted in situations where ambient and/or environmental interference can significantly degrade the measurement accuracy or cause the measurements be unreliable.
To facilitate a complete understanding of the invention, the remainder of the detailed description describes the invention with reference to the drawings, wherein like reference numbers are referenced with like numerals throughout.
The patient monitor can comprise a display 110 and one or more control buttons 108. In some embodiments, the display 110 can be a touch sensitive display that can include one or more virtual controls and/or changing display and/or control screens. The display 110 can be configured to display a wide variety of measured psychological parameters in a manner that provides for quick and efficient conveyance of information to a user. For example, the display 110 can show values for blood oxygen saturation, pulse, glucose, methemoglobin, total hemoglobin, and the like. In addition, as shown in
The sensor 202 can additionally comprise a temperature sensor 207, such as a thermistor or a thermocouple, and a memory device 208, such non-volatile (e.g., an EEPROM) or volatile memory. The sensor 202 also includes a plurality of conductors communicating signals to and from its components, including temperature sensor conductors 209, detector composite signal conductors 210, memory device conductors 214, and emitter drive signal conductors 216. In some embodiments, the sensor conductors 209, 210, 214, 216 communicate their signals to the monitor 203 through the cable 212. In some embodiments, the cable 212 includes a plurality of shielded conductors.
Although disclosed with reference to the cable 212, a skilled artisan will recognize from the disclosure herein that the communication to and from the sensor 202 may advantageously include a wide variety of cables, cable designs, public or private communication networks or computing systems, wired or wireless communications (such as Ethernet, Bluetooth or WiFi, including IEEE 802.11x), mobile communications, combinations of the same, or the like.
In some embodiments, the temperature sensor 207 monitors the temperature of the sensor 202 and its components, such as, for, example, the emitters 204. For example, in some embodiments, the temperature sensor 207 comprises or communicates with a thermal bulk mass having sufficient thermal conduction to generally approximate a real-time temperature of a substrate of the light emitters 204. In some embodiments, the monitor 203 may advantageously use the temperature sensor 207 output to, among other things, ensure patient safety, especially in applications with sensitive tissue 205. In some embodiments, the monitor 203 may advantageously use the temperature sensor 207 output and monitored operating current or voltages to correct for operating conditions of the sensor 202.
The memory 208 can comprise any one or more of a wide variety of memory devices known to a skilled artisan from the disclosure herein, including non-volatile memory, volatile memory, or combination thereof. The memory 208 can be configured to store some or all of a wide variety data and information, including, for example, information on the type or operation of the sensor 202, type of patient or body tissue 205, buyer or manufacturer information, sensor characteristics including the number of wavelengths capable of being emitted, emitter specifications, emitter drive requirements, demodulation data, calculation mode data, calibration data, software or firmware such as scripts, executable code, or the like, sensor electronic elements, sensor life data indicating whether some or all sensor components have expired and should be replaced, encryption information, monitor or algorithm upgrade instructions or data, or the like. In some embodiments, the memory device 208 may also include emitter wavelength correction data. In some embodiments, the monitor 203 can read the memory 208 to determine one, some or all of a wide variety of data and information stored. As is shown In
The monitor 203 can comprise a front end signal conditioner 222 configured to receive, through the conductors 210, the analog composite detector signal from the detectors 206. The signal conditioner 222 can normalize the analog composite detector signal by adjusting the signal's gain, remove unwanted frequency components by passing the signal through a band-pass or a low-pass filter, normalize the phase of the signal by passing it through an all-pass filter with the desired phase response, and the like. The signal conditioner 222 includes one or more outputs communicating with an analog-to-digital converter 226 (“A/D converter”). In some embodiments, the A/D converter 226 may comprise a delta-sigma converter to provide better linearity and signal-to-noise performance, which, among other things, advantageously enhances measurements during lower perfusion. The reduced signal-to-noise may also improve measurement quality by providing better rejection of ambient and/or environment interference (e.g., from electrocauterization devices). The A/D converter 226 includes inputs communicating with the output of the front end signal conditioner 222 and the output of the temperature sensor 207. The converter 226 also includes outputs for communicating the digitized composite detector signal values and temperature sensor readings to the processor 228.
The processor 228 can output an emitter driver current control signal 230 to a digital-to-analog converter 232 (“D/A converter”). The D/A converter 232 can supply control information to emitter driving circuitry 234, which in turns drives the plurality of emitters 204 on the sensor 202 over conductors 216. In some embodiments, the emitter driving circuitry 234 drives eight emitters capable of emitting light at eight predefined wavelengths, although the circuitry 234 can drive any number of emitters. In addition, one or more emitters could emit light at the same or substantially the same wavelength to provide redundancy. The circuitry 234 can be configured to modulate the emitters 204, by turning them on and off, as to produce pulse trains of light at the corresponding wavelengths. In some embodiments, the circuitry 234 can be configured to turn the emitters 204 off as to cause the detectors 206 to detect the level of ambient or environment noise, which can additionally modulate by the rectangular pulse train carrier signal. Further details of modulation are disclosed in U.S. Pat. No. 6,229,856, issued on May 8, 2001, the disclosure of which is incorporated by reference herein.
The processor 228 can process digitized composite detector signal values and calculate physiological parameter information, such as blood oxygen saturation, pulse, glucose, methemoglobin, total hemoglobin, and the like. The processor 228 comprises an interference detector 240 configured to calculate the levels of ambient and/or environment interference comprised in the composite detector signal. In some embodiments, the processor 228 can read the information stored in the memory device 208 and use the retrieved information for calculation of physiological parameter information and/or interference levels.
The processor 228 can communicate with the audio/visual interface 236, for example, to display the measured and calculated parameters or interference levels.
The audio/visual interface 236 can be configured as a display device capable of providing indicia representative of the calculated physiological parameters of the tissue 205 at the measurement site and of the calculated interference levels. In some embodiments, the audio/visual interface 236 can display trending data for one or more of the measured or determined parameters or interference levels. Moreover, an artisan will recognize from the disclosure herein many display options for the data available from the processor 228.
In addition, the processor 228 can communicate with local and/or remote storage 241 and local and/or remote network devices through network interface 242. Storage 241 can be configured as non-volatile memory, volatile memory or combination thereof. Storage 241 can be in the form of a hard disk, flash memory card, or other suitable computer accessible memory. In some embodiments, the processor 228 can store a variety of information in the storage 241, such as calculated physiological parameter information and interference levels. This information can be later retrieved and used in future calculations. In some embodiments, the processor can communicate variety of information to network devices over the network interface 242. The network interface 242 can be configured with a wide variety of cables, cable designs, public or private communication networks or computing systems, wired or wireless communications (such as Ethernet, Bluetooth or WiFi, including IEEE 802.11x), mobile communications, combinations of the same, or the like. The processor 228 can exchange a variety of information with network devices, such as calculated physiological parameter information and interference levels.
In some embodiments a demodulation module 403A models and demodulates the digitized composite detector signal 401A (e.g., a 48 KHz composite signal) to separate the composite signal into signals related to each emitted wavelength and to remove the frequency components of the carrier signal. In addition, the demodulation module 403A can be configured to model and demodulate the digitized composite detector signal to separate the interference signal into interference signals related to each emitted wavelength and to remove the frequency components of the carrier signal. In some embodiments the demodulation module 403A can be configured to model and demodulate digitized composite detector signal data into N (e.g., 8) channels of demodulated data. Each channel can be configured to correspond to a different frequency and/or phase characteristics. For example, each channel can correspond to a fundamental frequency and its harmonics of the rectangular light pulse train carrier signal modulated by the light signal emitted by an emitter 204. Furthermore, as explained below, several channels can share the same frequency characteristic, and, in such embodiments, phase can be used to distinguish these channels.
The multiple channels of demodulated data samples can be presented to a decimation module 404A, which is configured to reduce the sampling rate by eliminating samples and, additionally, may provide signal conditioning and filtering. Because decimation reduces the number of data samples, it can reduce computational burden on the digital signal processor and interference detector 428 and, additionally, reduce power consumption of the patient monitor. In some embodiments, a 48 KHz demodulated multiple channel data stream can be decimated to 62.5 Hz.
To determine the interference levels, the multiple channels of demodulated and decimated data can be presented to an energy detector 405A. In some embodiments, the composite detector signal xk(n) 401A can comprise only the interference signal, as the emitters 204 can be configured (e.g., by the circuitry 234) to be off. Then, the multiple channels of demodulated and decimated data comprise interference signals, and the energy detector 405A can be configured to compute the energy or power of the interference signals. In some embodiments, as is explained below, the energy detector 405A can compute the average power of the interference signal on each of the decimation channels and to select the maximum power value as the interference output.
To compute physiological parameter information, such as blood oxygen saturation, pulse, glucose, methemoglobin, total hemoglobin, and the like, the multiple channels of demodulated and decimated data can be presented to a parameter calculator 406A. The parameter calculator 406A can model, condition, and process the data according to various algorithms for computation of physiological information, as is described in U.S. application Ser. No. 11/367,017 (filed Mar. 1, 2006), the disclosure of which is incorporated by reference herein.
A demodulation module 403B models and demodulates the digitized composite detector signal xk(n) 401B (e.g., a 48 KHz composite signal) to separate the interference signal into interference signals related to each emitted wavelength and to remove the frequency components of the carrier signal. As is illustrated in
In some embodiments, a modulated light signal can be produced by modulating a periodic, rectangular pulse train (i.e., the carrier signal) by the light produced by the emitters 204. The circuit 234 can be configured such that only one emitter 204 (e.g., light emitting diodes) is active at any given time period. For example, if there are two emitters 204 (e.g., red and infrared light emitting diodes), the circuit 234 can apply current to activate the first emitter during a first time interval of duration τ1, while keeping the second emitter inactive. Thereafter, no current can be applied to either emitter during a second time interval of duration τ2. Then, the current can be applied to activate the second emitter during a third time interval of duration τ3, while keeping the first emitter inactive. Finally, the modulation cycle can be completed by applying no current to either emitter during a fourth time interval τ4. Thereafter, the cycle can be repeated by restarting with the first interval. All four time intervals τ1, τ3, τ3, and τ4 can be of the same duration τ. Accordingly, the carrier signal, a periodic, rectangular pulse train having a pulse width τ and a period of 4τ and corresponding Fourier coefficients of τF0*sin c(kF0τ), where F0 is the fundamental frequency (i.e. inverse of the period) and k=±1, ±2, . . . , is modulated by the light emitted by emitters 204. The Fourier coefficients correspond to the fundamental frequency and its harmonics (or integer multiples of the fundamental frequency). The circuit 234 can be configured to similarly modulate any number of carrier signals by any number of emitters 204, such as 8 emitters.
In order to recover the intensity of the light signal, attenuated through the tissue 205 and detected by the detectors 206, the demodulation module 403B can be configured to model and analyze the composite detector signal 401B at the fundamental frequency F0 and the harmonics of the periodic pulse train (“frequencies of interest”). This can be accomplished by shifting the envelope of the modulated signal (i.e. composite detector signal), or part of the envelope that comprises a significant energy of the intensity signal, to a frequency of interest and then applying a filter to remove components at other higher frequencies. In some embodiments, several frequencies of interest can be used and shifting of the envelope can be accomplished by multiplying the modulated signal by a cosine or sine signal having the frequency corresponding to the frequency of interest. A skilled artisan will recognize from the disclosure herein that frequencies of interest can be frequencies other than the fundamental frequency F0 and its harmonics and demodulations methods other than shifting the signal envelope can be used.
In some embodiments, the demodulation module 403B can be further configured to reduce or eliminate in the composite detector signal crosstalk between the light signals output by different emitters 204. For example, if there are two emitters 204 (e.g., red and infrared light emitting diode), crosstalk in the composite detector signal can be defined as the effect of the red light signal on the infrared light signal and vice versa. Such crosstalk can be minimized or eliminated by selecting appropriate demodulating signals and multiplying these by the composite detector signal. In some embodiments as is explained in the above-identified issued U.S. Pat. No. 6,229,856, demodulating signals reducing or eliminating crosstalk can be configured as cosine signals with frequencies of the fundamental frequency F0 and harmonics of the carrier pulse train: C1 cos (2πF0t), C2 cos (4πF0t), C3 cos (6πF0t), and so on (where C1, C2, C3, . . . are constants selected to minimize or eliminate crosstalk).
Additionally, selecting frequencies of interest can result in reducing the effect of at least some types and intensities of ambient or environment noise on the light intensity signals. For example, the fundamental frequency F0 can be selected as 316.7 Hz (i.e., with harmonics at 316.7 n Hz, where n is an integer value) to reduce or eliminate the effect of power line noise (60 Hz or 50 Hz fundamental frequency with harmonics at 60 n Hz or 50 n Hz, where n is an integer value). Accordingly, the nearest harmonic of power line noise to the light signal intensity comprised by the modulated pulse train having the fundamental frequency of 316.7 Hz would be 300 and 360 Hz, for 60 Hz power line frequency, and 300 and 350 Hz, for 50 Hz power line frequency. This would provide a frequency separation of noise and light intensity. In some embodiments, the fundamental frequency F0 can be selected as 330 Hz to provide the separation.
Accordingly, in some embodiments, the demodulation module 403B of the interference detector 440B can be configured to model and analyze the composite detector signal 401B, which comprises interference, at the fundamental frequency F0 and its harmonics. Accordingly, the demodulation module 403B operates at the modulation frequency and its harmonics as applied to demodulate the modulated composite light signal. As is explained above, interference signals having components at these frequencies of interest can significantly degrade the recovery of the light intensity signals from the composite detector signal. Therefore, it is advantageous to determine the level of interference at these frequencies of interest and to compute the likelihood of successful recovery and processing of the light intensity signals given in the presence of ambient and/or environment interference. In some embodiments, the demodulation module 403B can be configured to model the interference signal at the fundamental frequency and the second, third, and fourth harmonics. However, a skilled artisan will recognize a wide variety of signal modeling combinations from the disclosure herein.
Furthermore, the demodulation module 403B can be configured to model the full energy spectrum of the interference signal at the frequencies of interest. This can be accomplished by capturing the energy of the interference signal at the frequencies of interest regardless of the phase variation of the interference signal at those frequencies. In some embodiments, this can be accomplished by using both cosine and sine as demodulating signals. Because cosine and sine signals of the same frequency are π/2 radians out of phase, using these as complementary demodulating signals can model and capture all of the potential interference signal energy at the frequencies of interest. In some embodiments, the spectrum of the interference signal can be modeled by using only a cosine or only a sine demodulating signal. A skilled artisan will recognize a wide variety of demodulating signals, such as orthogonal signals, from the disclosure herein.
As is illustrated in
The demodulated interference signal data can be presented to a decimation module 404B, which reduces the sampling rate by eliminating samples and, additionally, may provide signal conditioning and filtering. Because decimation reduces the number of data samples, it can reduce computational burden on the interference detector 440B and, additionally, reduce power consumption of the patient monitor. As is illustrated in
The demodulated, decimated interference signal data can be presented to an energy detector 405B for calculation of interference levels. A signal's energy can be calculated by summing up squared absolute values of the signal samples. As is illustrated in
In some embodiments, the calculated energy or power computed for complementary cosine and sine channels sharing the same frequency can be summed in order to determine energy or power of the interference signal at each frequency of interest. As is explained above, because cosine and sine signals of the same frequency are π/2 radians out of phase, using both as complementary demodulating signals can model and capture all of the potential interference signal energy at the frequencies of interest. As is illustrated in
The interference level (or output) computed by the interference detector 440B for the digitized composite detector signal xk(n) 401B can be the maximum computed energy or power at the frequencies of interest. As is illustrated in
The maximum computed energy or power of the interference signal (or interference output) can be communicated to the user at 507. In some embodiments, the interference output can be presented to the user visually as, for example, in a bar graph. As is illustrated in
As is illustrated in
In some embodiments, the patient monitor can be configured to provide audio notification to the user. For example, after computing the interference output and comparing it to the threshold, the patient monitor can sound the phrase “Safe to Measure” when the interference output is below the threshold. As another example, the patient monitor can sound the phrase “Danger” when the interference output is close or above the threshold. A skilled artisan will recognize a variety of audio/visual notification techniques from the disclosure herein.
Although the interference detector for a patient monitor is disclosed with reference to its preferred embodiment, the invention is not intended to be limited thereby. Rather, a skilled artisan will recognize from the disclosure herein a wide number of alternatives for the interference detector for patient monitor. For example, the patient monitor can “lock out” the user from performing measurements of physiological parameters when the computed interference levels are determined to significantly degrade the accuracy of the measurements.
In addition to those processes described above, other processes and combination of processes will be apparent to those of skill in the art from the present disclosure. Those of skill will further appreciate that the various illustrative logical blocks, modules, and steps described in connection with the embodiments disclosed herein may be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. Skilled artisans can implement the described functionality in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the present invention.
The various illustrative logical blocks, modules, and steps described in connection with the embodiments disclosed herein can be implemented or performed with a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general purpose processor can be a microprocessor, conventional processor, controller, microcontroller, state machine, etc. A processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration. In addition, the term “processing” is a broad term meant to encompass several meanings including, for example, implementing program code, executing instructions, manipulating signals, filtering, performing arithmetic operations, and the like.
The modules can include, but are not limited to, any of the following: software or hardware components such as software, object-oriented software components, class components and task components, processes, methods, functions, attributes, procedures, subroutines, segments of program code, drivers, firmware, microcode, circuitry, data, databases, data structures, tables, arrays, or variables.
The steps of a method or algorithm described in connection with the embodiments disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, a DVD, or any other form of storage medium known in the art. A storage medium is coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.
Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Additionally, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. It is contemplated that various aspects and features of the invention described can be practiced separately, combined together, or substituted for one another, and that a variety of combinations and subcombinations of the features and aspects can be made and still fall within the scope of the invention. Furthermore, the systems described above need not include all of the modules and functions described in the preferred embodiments. Accordingly, the present invention is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.
Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The present application is a continuation of U.S. patent application Ser. No. 12/841,965, filed Jul. 22, 2010, entitled “Interference Detector for Patient Monitor,” which claims priority benefit from U.S. Provisional Application No. 61/228,495, filed Jul. 24, 2009, entitled “Interference Detector for Patient Monitor,” both of which are incorporated herein by reference. The present application is related to U.S. Pat. No. 5,919,134, filed Jan. 12, 1998, entitled “Method and Apparatus for Demodulating Signals in Pulse Oximetry Systems”; and U.S. Pat. No. 6,526,300, filed Jun. 16, 2000, entitled “Pulse Oximeter Probe-Off Detection System, both of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4960128 | Gordon et al. | Oct 1990 | A |
4964408 | Hink et al. | Oct 1990 | A |
5041187 | Hink et al. | Aug 1991 | A |
5069213 | Polczynski | Dec 1991 | A |
5163438 | Gordon et al. | Nov 1992 | A |
5319355 | Russek | Jun 1994 | A |
5337744 | Branigan | Aug 1994 | A |
5341805 | Stavridi et al. | Aug 1994 | A |
D353195 | Savage et al. | Dec 1994 | S |
D353196 | Savage et al. | Dec 1994 | S |
5377676 | Vari et al. | Jan 1995 | A |
D359546 | Savage et al. | Jun 1995 | S |
5431170 | Mathews | Jul 1995 | A |
D361840 | Savage et al. | Aug 1995 | S |
D362063 | Savage et al. | Sep 1995 | S |
5452717 | Branigan et al. | Sep 1995 | A |
D363120 | Savage et al. | Oct 1995 | S |
5456252 | Vari et al. | Oct 1995 | A |
5479934 | Imran | Jan 1996 | A |
5482036 | Diab et al. | Jan 1996 | A |
5490505 | Diab et al. | Feb 1996 | A |
5494043 | O'Sullivan et al. | Feb 1996 | A |
5533511 | Kaspari et al. | Jul 1996 | A |
5534851 | Russek | Jul 1996 | A |
5561275 | Savage et al. | Oct 1996 | A |
5562002 | Lalin | Oct 1996 | A |
5590649 | Caro et al. | Jan 1997 | A |
5602924 | Durand et al. | Feb 1997 | A |
5632272 | Diab et al. | May 1997 | A |
5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
5638818 | Diab et al. | Jun 1997 | A |
5645440 | Tobler et al. | Jul 1997 | A |
5685299 | Diab et al. | Nov 1997 | A |
D393830 | Tobler et al. | Apr 1998 | S |
5743262 | Lepper, Jr. et al. | Apr 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5760910 | Lepper, Jr. et al. | Jun 1998 | A |
5769785 | Diab et al. | Jun 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5785659 | Caro et al. | Jul 1998 | A |
5791347 | Flaherty et al. | Aug 1998 | A |
5810734 | Caro et al. | Sep 1998 | A |
5823950 | Diab et al. | Oct 1998 | A |
5830131 | Caro et al. | Nov 1998 | A |
5833618 | Caro et al. | Nov 1998 | A |
5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
5890929 | Mills et al. | Apr 1999 | A |
5904654 | Wohltmann et al. | May 1999 | A |
5919134 | Diab | Jul 1999 | A |
5934925 | Tobler et al. | Aug 1999 | A |
5940182 | Lepper, Jr. et al. | Aug 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5997343 | Mills et al. | Dec 1999 | A |
6002952 | Diab et al. | Dec 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6027452 | Flaherty et al. | Feb 2000 | A |
6036642 | Diab et al. | Mar 2000 | A |
6045509 | Caro et al. | Apr 2000 | A |
6067462 | Diab et al. | May 2000 | A |
6081735 | Diab et al. | Jun 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6110522 | Lepper, Jr. et al. | Aug 2000 | A |
6124597 | Shehada | Sep 2000 | A |
6128521 | Marro et al. | Oct 2000 | A |
6129675 | Jay | Oct 2000 | A |
6144868 | Parker | Nov 2000 | A |
6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
6152754 | Gerhardt et al. | Nov 2000 | A |
6157850 | Diab et al. | Dec 2000 | A |
6165005 | Mills et al. | Dec 2000 | A |
6184521 | Coffin, IV et al. | Feb 2001 | B1 |
6206830 | Diab et al. | Mar 2001 | B1 |
6229856 | Diab et al. | May 2001 | B1 |
6232609 | Snyder et al. | May 2001 | B1 |
6236872 | Diab et al. | May 2001 | B1 |
6241683 | Macklem et al. | Jun 2001 | B1 |
6253097 | Aronow et al. | Jun 2001 | B1 |
6256523 | Diab et al. | Jul 2001 | B1 |
6263222 | Diab et al. | Jul 2001 | B1 |
6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
6280213 | Tobler et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6301493 | Marro et al. | Oct 2001 | B1 |
6317627 | Ennen et al. | Nov 2001 | B1 |
6321100 | Parker | Nov 2001 | B1 |
6325761 | Jay | Dec 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6343224 | Parker | Jan 2002 | B1 |
6349228 | Kiani et al. | Feb 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6371921 | Caro et al. | Apr 2002 | B1 |
6377829 | Al-Ali | Apr 2002 | B1 |
6388240 | Schulz et al. | May 2002 | B2 |
6397091 | Diab et al. | May 2002 | B2 |
6430437 | Marro | Aug 2002 | B1 |
6430525 | Weber et al. | Aug 2002 | B1 |
6463311 | Diab | Oct 2002 | B1 |
6470199 | Kopotic et al. | Oct 2002 | B1 |
6501975 | Diab et al. | Dec 2002 | B2 |
6505059 | Kollias et al. | Jan 2003 | B1 |
6515273 | Al-Ali | Feb 2003 | B2 |
6519487 | Parker | Feb 2003 | B1 |
6525386 | Mills et al. | Feb 2003 | B1 |
6526300 | Kiani et al. | Feb 2003 | B1 |
6541756 | Schulz et al. | Apr 2003 | B2 |
6542764 | Al-Ali et al. | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6595316 | Cybulski et al. | Jul 2003 | B2 |
6597932 | Tian et al. | Jul 2003 | B2 |
6597933 | Kiani et al. | Jul 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6632181 | Flaherty et al. | Oct 2003 | B2 |
6639668 | Trepagnier | Oct 2003 | B1 |
6640116 | Diab | Oct 2003 | B2 |
6643530 | Diab et al. | Nov 2003 | B2 |
6650917 | Diab et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6671531 | Al-Ali et al. | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6684091 | Parker | Jan 2004 | B2 |
6697656 | Al-Ali | Feb 2004 | B1 |
6697657 | Shehada et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
RE38476 | Diab et al. | Mar 2004 | E |
6699194 | Diab et al. | Mar 2004 | B1 |
6714804 | Al-Ali et al. | Mar 2004 | B2 |
RE38492 | Diab et al. | Apr 2004 | E |
6721582 | Trepagnier et al. | Apr 2004 | B2 |
6721585 | Parker | Apr 2004 | B1 |
6725075 | Al-Ali | Apr 2004 | B2 |
6728560 | Kollias et al. | Apr 2004 | B2 |
6735459 | Parker | May 2004 | B2 |
6745060 | Diab et al. | Jun 2004 | B2 |
6760607 | Al-Ali | Jul 2004 | B2 |
6770028 | Ali et al. | Aug 2004 | B1 |
6771994 | Kiani et al. | Aug 2004 | B2 |
6792300 | Diab et al. | Sep 2004 | B1 |
6813511 | Diab et al. | Nov 2004 | B2 |
6816741 | Diab | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6826419 | Diab et al. | Nov 2004 | B2 |
6830711 | Mills et al. | Dec 2004 | B2 |
6850787 | Weber et al. | Feb 2005 | B2 |
6850788 | Al-Ali | Feb 2005 | B2 |
6852083 | Caro et al. | Feb 2005 | B2 |
6861639 | Al-Ali | Mar 2005 | B2 |
6898452 | Al-Ali et al. | May 2005 | B2 |
6920345 | Al-Ali et al. | Jul 2005 | B2 |
6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
6934570 | Kiani et al. | Aug 2005 | B2 |
6939305 | Flaherty et al. | Sep 2005 | B2 |
6943348 | Coffin, IV | Sep 2005 | B1 |
6950687 | Al-Ali | Sep 2005 | B2 |
6961598 | Diab | Nov 2005 | B2 |
6970792 | Diab | Nov 2005 | B1 |
6979812 | Al-Ali | Dec 2005 | B2 |
6985764 | Mason et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
6999904 | Weber et al. | Feb 2006 | B2 |
7003338 | Weber et al. | Feb 2006 | B2 |
7003339 | Diab et al. | Feb 2006 | B2 |
7015451 | Dalke et al. | Mar 2006 | B2 |
7024233 | Ali et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7039449 | Al-Ali | May 2006 | B2 |
7041060 | Flaherty et al. | May 2006 | B2 |
7044918 | Diab | May 2006 | B2 |
7067893 | Mills et al. | Jun 2006 | B2 |
7096052 | Mason et al. | Aug 2006 | B2 |
7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
7132641 | Schulz et al. | Nov 2006 | B2 |
7142901 | Kiani et al. | Nov 2006 | B2 |
7149561 | Diab | Dec 2006 | B2 |
7186966 | Al-Ali | Mar 2007 | B2 |
7190261 | Al-Ali | Mar 2007 | B2 |
7215984 | Diab | May 2007 | B2 |
7215986 | Diab | May 2007 | B2 |
7221971 | Diab | May 2007 | B2 |
7225006 | Al-Ali et al. | May 2007 | B2 |
7225007 | Al-Ali | May 2007 | B2 |
RE39672 | Shehada et al. | Jun 2007 | E |
7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
7245953 | Parker | Jul 2007 | B1 |
7254429 | Schurman et al. | Aug 2007 | B2 |
7254431 | Al-Ali | Aug 2007 | B2 |
7254433 | Diab et al. | Aug 2007 | B2 |
7254434 | Schulz et al. | Aug 2007 | B2 |
7272425 | Al-Ali | Sep 2007 | B2 |
7274955 | Kiani et al. | Sep 2007 | B2 |
D554263 | Al-Ali | Oct 2007 | S |
7280858 | Al-Ali et al. | Oct 2007 | B2 |
7289835 | Mansfield et al. | Oct 2007 | B2 |
7292883 | De Felice et al. | Nov 2007 | B2 |
7295866 | Al-Ali | Nov 2007 | B2 |
7328053 | Diab et al. | Feb 2008 | B1 |
7332784 | Mills et al. | Feb 2008 | B2 |
7340287 | Mason et al. | Mar 2008 | B2 |
7341559 | Schulz et al. | Mar 2008 | B2 |
7343186 | Lamego et al. | Mar 2008 | B2 |
D566282 | Al-Ali et al. | Apr 2008 | S |
7355512 | Al-Ali | Apr 2008 | B1 |
7356365 | Schurman | Apr 2008 | B2 |
7371981 | Abdul-Hafiz | May 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7373194 | Weber et al. | May 2008 | B2 |
7376453 | Diab et al. | May 2008 | B1 |
7377794 | Al-Ali et al. | May 2008 | B2 |
7377899 | Weber et al. | May 2008 | B2 |
7383070 | Diab et al. | Jun 2008 | B2 |
7415297 | Al-Ali et al. | Aug 2008 | B2 |
7428432 | Ali et al. | Sep 2008 | B2 |
7438683 | Al-Ali et al. | Oct 2008 | B2 |
7440787 | Diab | Oct 2008 | B2 |
7454240 | Diab et al. | Nov 2008 | B2 |
7467002 | Weber et al. | Dec 2008 | B2 |
7469157 | Diab et al. | Dec 2008 | B2 |
7471969 | Diab et al. | Dec 2008 | B2 |
7471971 | Diab et al. | Dec 2008 | B2 |
7483729 | Al-Ali et al. | Jan 2009 | B2 |
7483730 | Diab et al. | Jan 2009 | B2 |
7489958 | Diab et al. | Feb 2009 | B2 |
7496391 | Diab et al. | Feb 2009 | B2 |
7496393 | Diab et al. | Feb 2009 | B2 |
D587657 | Al-Ali et al. | Mar 2009 | S |
7499741 | Diab et al. | Mar 2009 | B2 |
7499835 | Weber et al. | Mar 2009 | B2 |
7500950 | Al-Ali et al. | Mar 2009 | B2 |
7509154 | Diab et al. | Mar 2009 | B2 |
7509494 | Al-Ali | Mar 2009 | B2 |
7510849 | Schurman et al. | Mar 2009 | B2 |
7526328 | Diab et al. | Apr 2009 | B2 |
7530942 | Diab | May 2009 | B1 |
7530949 | Al Ali et al. | May 2009 | B2 |
7530955 | Diab et al. | May 2009 | B2 |
7563110 | Al-Ali et al. | Jul 2009 | B2 |
7572230 | Neumann et al. | Aug 2009 | B2 |
7596398 | Al-Ali et al. | Sep 2009 | B2 |
7618375 | Flaherty et al. | Nov 2009 | B2 |
D606659 | Kiani et al. | Dec 2009 | S |
7647083 | Al-Ali et al. | Jan 2010 | B2 |
D609193 | Al-Ali et al. | Feb 2010 | S |
D614305 | Al-Ali et al. | Apr 2010 | S |
RE41317 | Parker | May 2010 | E |
7729733 | Al-Ali et al. | Jun 2010 | B2 |
7734320 | Al-Ali | Jun 2010 | B2 |
7761127 | Al-Ali et al. | Jul 2010 | B2 |
7761128 | Al-Ali et al. | Jul 2010 | B2 |
7764982 | Dalke et al. | Jul 2010 | B2 |
D621516 | Kiani et al. | Aug 2010 | S |
7791155 | Diab | Sep 2010 | B2 |
7801581 | Diab | Sep 2010 | B2 |
7822452 | Schurman et al. | Oct 2010 | B2 |
RE41912 | Parker | Nov 2010 | E |
7844313 | Kiani et al. | Nov 2010 | B2 |
7844314 | Al-Ali | Nov 2010 | B2 |
7844315 | Al-Ali | Nov 2010 | B2 |
7865222 | Weber et al. | Jan 2011 | B2 |
7873497 | Weber et al. | Jan 2011 | B2 |
7880606 | Al-Ali | Feb 2011 | B2 |
7880626 | Al-Ali et al. | Feb 2011 | B2 |
7891355 | Al-Ali et al. | Feb 2011 | B2 |
7894868 | Al-Ali et al. | Feb 2011 | B2 |
7899507 | Al-Ali et al. | Mar 2011 | B2 |
7899518 | Trepagnier et al. | Mar 2011 | B2 |
7904132 | Weber et al. | Mar 2011 | B2 |
7909772 | Popov et al. | Mar 2011 | B2 |
7910875 | Al-Ali | Mar 2011 | B2 |
7919713 | Al-Ali et al. | Apr 2011 | B2 |
7937128 | Al-Ali | May 2011 | B2 |
7937129 | Mason et al. | May 2011 | B2 |
7937130 | Diab et al. | May 2011 | B2 |
7941199 | Kiani | May 2011 | B2 |
7951086 | Flaherty et al. | May 2011 | B2 |
7957780 | Lamego et al. | Jun 2011 | B2 |
7962188 | Kiani et al. | Jun 2011 | B2 |
7962190 | Diab et al. | Jun 2011 | B1 |
7976472 | Kiani | Jul 2011 | B2 |
7988637 | Diab | Aug 2011 | B2 |
7990382 | Kiani | Aug 2011 | B2 |
7991446 | Ali et al. | Aug 2011 | B2 |
8000761 | Al-Ali | Aug 2011 | B2 |
8008088 | Bellott et al. | Aug 2011 | B2 |
RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
8019400 | Diab et al. | Sep 2011 | B2 |
8028701 | Al-Ali et al. | Oct 2011 | B2 |
8029765 | Bellott et al. | Oct 2011 | B2 |
8036728 | Diab et al. | Oct 2011 | B2 |
8046040 | Ali et al. | Oct 2011 | B2 |
8046041 | Diab et al. | Oct 2011 | B2 |
8046042 | Diab et al. | Oct 2011 | B2 |
8048040 | Kiani | Nov 2011 | B2 |
8050728 | Al-Ali et al. | Nov 2011 | B2 |
20070043269 | Mannheimer et al. | Feb 2007 | A1 |
20090156924 | Shariati et al. | Jun 2009 | A1 |
20110109459 | Poeze et al. | May 2011 | A1 |
Number | Date | Country |
---|---|---|
WO 2008141306 | Nov 2008 | WO |
Entry |
---|
International Search Report and Written Opinion of the International Searching Authority issued in Application No. PCT/US2010/043120, mailed Oct. 27, 2010 in 15 pages. |
Number | Date | Country | |
---|---|---|---|
20130278430 A1 | Oct 2013 | US |
Number | Date | Country | |
---|---|---|---|
61228495 | Jul 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12841965 | Jul 2010 | US |
Child | 13918206 | US |